Research programme: antibody therapeutics - Immunomedics
Alternative Names: 1R-(15)-(15); MN-14; MN-15; MN-3; MN-6Latest Information Update: 02 Oct 2021
At a glance
- Originator Immunomedics
- Class Drug conjugates; Fab fragments; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action Immunomodulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer
Most Recent Events
- 23 Oct 2020 Immunomedics has been acquired by Gilead Sciences
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)